Axsome Therapeutics Inc (AXSM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Axsome Therapeutics Inc (AXSM) has a cash flow conversion efficiency ratio of -0.396x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.95 Million) by net assets ($83.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Axsome Therapeutics Inc (AXSM) market capitalisation for the company's overall valuation and market capitalisation.
Axsome Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Axsome Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Axsome Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Axsome Therapeutics Inc ranked by their cash flow conversion efficiency. See debt repayment capacity of Axsome Therapeutics Inc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Strabag SE
VI:STR
|
-0.037x |
|
Encompass Health Corp
NYSE:EHC
|
0.093x |
|
China Resources Microelectronics Ltd
SHG:688396
|
0.026x |
|
RenaissanceRe Holdings Ltd
F:RRJ
|
0.037x |
|
EastGroup Properties Inc
NYSE:EGP
|
0.045x |
|
Ningbo Tuopu Group Co Ltd
SHG:601689
|
0.061x |
|
Sociedad Química y Minera de Chile S.A.
SN:SQM-B
|
0.206x |
|
Lululemon Athletica Inc.
NASDAQ:LULU
|
0.044x |
Annual Cash Flow Conversion Efficiency for Axsome Therapeutics Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Axsome Therapeutics Inc from 2013 to 2025. View latest Axsome Therapeutics Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $88.30 Million | $-93.41 Million | -1.058x | +53.03% |
| 2024-12-31 | $57.02 Million | $-128.41 Million | -2.252x | -196.47% |
| 2023-12-31 | $190.98 Million | $-145.08 Million | -0.760x | +28.57% |
| 2022-12-31 | $109.56 Million | $-116.51 Million | -1.063x | +84.64% |
| 2021-12-31 | $15.63 Million | $-108.23 Million | -6.924x | -904.27% |
| 2020-12-31 | $113.79 Million | $-78.46 Million | -0.689x | -165.71% |
| 2019-12-31 | $178.72 Million | $-46.38 Million | -0.259x | +99.19% |
| 2018-12-31 | $937.92K | $-30.05 Million | -32.043x | -1923.55% |
| 2017-12-31 | $16.72 Million | $-26.47 Million | -1.583x | -60.51% |
| 2016-12-31 | $21.57 Million | $-21.28 Million | -0.987x | -515.94% |
| 2015-12-31 | $46.44 Million | $-7.44 Million | -0.160x | -111.16% |
| 2014-12-31 | $-3.20 Million | $-4.60 Million | 1.435x | +78.43% |
| 2013-12-31 | $-2.03 Million | $-1.63 Million | 0.804x | -- |
About Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment… Read more